09:24 AM EDT, 08/12/2025 (MT Newswires) -- Elicio Therapeutics ( ELTX ) said Tuesday that data from its phase-1 study evaluating ELI-002 in patients with mutant KRAS-driven solid tumors showed improvements in overall survival and relapse-free survival in patients with pancreatic ductal adenocarcinoma, a type of pancreatic cancer.

The company said that among patients treated with its drug candidate, there was a 77% reduction in the risk of death and an 88% reduction in the risk of relapse, associated with T cell responses above the threshold for anti-tumor efficacy.

It added that at an extended follow-up 19.7 months after dosing, median overall survival increased to 28.94 months from 16.33 months.

The follow-up data, published in the Nature Medicine journal, demonstrated that with extended follow-up, 17 of the 25 participants whose T cell responses exceeded the antitumor efficacy threshold experienced a significantly reduced risk for relapse or death, the company said.

Shares of the company were up more than 15% in recent Tuesday premarket activity.